Kochi | FY26 Performance Dashboard (April 2025 - January 2026)
YTD: Jan'2610 Months
📊 Executive Summary
🏥 Department Performance
👨⚕️ Doctor Scorecard
📈 Budget vs Actual
⚠️ Concentration Risk
📅 Monthly Trends
💳 Payor Mix
🎯 YoY Growth
✅ Priorities & Actions
📐 Benchmarks
YTD Revenue
₹358.60 Cr
10 Months
IP Revenue
₹266.71 Cr
74.3% of total
OP Revenue
₹91.89 Cr
25.7% of total
IP Discharges
19,092
YTD total
ARPP-IP
₹1.40L
Avg package value
Bed Occupancy
62.0%
YTD average
⚠️ Critical Alert: Budget Shortfall
YTD revenue is ₹11.40 Cr (-3.1%) below budget target of ₹370 Cr. IP discharges at 19,092 vs target 20,000 (-4.5%) are the primary driver. ARPP-IP decline of ₹4K (-2.8%) and lower occupancy (62.0% vs 65.0% target) contributing factors. Urgent focus needed on discharge volume and case mix improvement.
✓ Positive Momentum: Strong Closing
January 2026 delivered strongest month at ₹37.41 Cr revenue with occupancy recovering to 63.8% — highest in YTD period. ARPP-IP reached ₹1,41,671 in Jan. This momentum, if sustained, could bridge FY26 gap by year-end. IP discharges trending upward (1,963 in Jan vs 1,842 in Apr). OP footfall consistently strong at 34,429 in Jan.
Monthly Revenue Trend (IP vs OP)
10-month performance April 2025 - January 2026
Revenue Split: IP vs OP (YTD)
Composition of ₹358.60 Cr total
Monthly Performance Summary
Key metrics by month April 2025 - January 2026
Month
Total Rev (Cr)
IP Rev (Cr)
OP Rev (Cr)
IP Disc
OP Footfall
ALOS (d)
ARPP-IP (₹)
Occ %
Total Departments
22
Specialist centers
Top Dept (Nephrology)
₹62.80 Cr
17.5% of revenue
Top 5 Revenue
₹194.40 Cr
54.2% of total
Highest ARPP-IP
₹5.07L
Liver Transplant
Highest ALOS
12.4 days
Liver Transplant
IP Specialists
79
Total doctors
✓ Department Concentration & Growth
Top 5 departments (Nephrology, Medical Oncology, GI Surgery, Neuro Surgery, Gastroenterology) contribute 54.2% of revenue at ₹194.40 Cr. Nephrology leads with ₹62.80 Cr and highest specialist count (6 doctors). Liver Transplant shows premium positioning with ₹5.07L ARPP-IP despite lowest case volume (342 discharges). Concentration risk mitigated by broad departmental base spanning 22 specialties.
Department Performance Matrix (YTD Jan'26)
Complete departmental metrics including volume, revenue, and efficiency
Department
Total (Cr)
IP (Cr)
OP (Cr)
IP Disc
OP Visits
ARPP-IP (₹)
ALOS
Docs
Top 6 Departments Revenue Breakdown
Doctor contribution within leading departments
Department ARPP-IP Comparison
Average revenue per patient by specialty
Filter by Department:
Top 12 Doctors - Revenue Scorecard (YTD Jan'26)
Ranked by total revenue contribution with department & performance metrics
Rank
Doctor Name
Department
Total (Cr)
IP (Cr)
OP (Cr)
IP Disc
OP Visits
ARPP-IP (₹)
BCG
Total Revenue Variance
-₹11.40 Cr
-3.1% vs Budget
IP Revenue Variance
-₹10.79 Cr
-3.9% vs Budget
IP Discharge Shortfall
-908
-4.5% vs Target
ARPP-IP Decline
-₹4,000
-2.8% vs Target
Occupancy Gap
-3.0 ppt
62.0% vs 65.0%
OP Revenue Variance
-₹0.61 Cr
-0.7% vs Budget
⚠️ Gap Driver Analysis
IP discharge volume shortfall (-908 cases, -4.5%) is the primary gap driver, accounting for ~65% of revenue miss. Secondary factors: ARPP-IP decline of ₹4K (-2.8%) from lower case complexity, and occupancy below target (62% vs 65%) reducing bed utilization. OP segment performing relatively well (-0.7% only). Strategic focus on case acquisition, case mix optimization, and occupancy recovery critical for H2.
Key Metrics: Budget vs Actual
YTD Jan'26 variance analysis
Metric
Budget
Actual
Variance
Var %
Total Revenue (Cr)
370.00
358.60
-11.40
-3.1%
IP Revenue (Cr)
277.50
266.71
-10.79
-3.9%
OP Revenue (Cr)
92.50
91.89
-0.61
-0.7%
IP Discharges
20,000
19,092
-908
-4.5%
ARPP-IP (₹L)
1.44
1.40
-0.04
-2.8%
Bed Occupancy %
65.0
62.0
-3.0ppt
-4.6%
Monthly Revenue: Budget vs Actual
Trend comparison across 10-month period
Variance Waterfall: Total Revenue Gap
IP volume, ARPP, occupancy, and OP impact
Top 2 Doctors Revenue
₹95.46 Cr
26.6% of YTD
Top 5 Doctors Revenue
₹144.66 Cr
40.3% of YTD
Abi Abraham (Nephrology)
₹48.62 Cr
13.5% of revenue
Gangadharan VP (Oncology)
₹46.84 Cr
13.0% of revenue
Herfindahl Index
0.142
Moderate concentration
Turnover Impact
-₹95.46 Cr
If top 2 depart
⚠️ Single-Doctor Dependency Risk
Top 2 doctors (Abi Abraham & Gangadharan VP) contribute ₹95.46 Cr (26.6%) — combined departure would create significant revenue gap. Abi Abraham alone brings ₹48.62 Cr from high-value Nephrology cases (₹3.48L ARPP-IP). Top 5 doctors account for 40.3% of YTD revenue. Herfindahl index of 0.142 indicates moderate-to-high concentration risk. Succession planning and mentorship of junior specialists essential.
Revenue Concentration: Pareto (80/20) Analysis
Doctor contribution to YTD revenue
Top 10 Doctors: Cumulative Revenue Share
Revenue concentration across physician base
Departure Scenario Impact Analysis
Revenue impact if key doctors leave LHRC
Scenario
Doctor(s)
Revenue Loss (Cr)
Impact %
Severity
Single-doctor loss
Abi Abraham
-48.62
-13.5%
Critical
Single-doctor loss
Gangadharan VP
-46.84
-13.0%
Critical
Twin-doctor loss
Top 2 combined
-95.46
-26.6%
Severe
Top 5 loss
5 leading doctors
-144.66
-40.3%
Catastrophic
Risk Mitigation Recommendations
Strategic actions for concentration management
Risk Dimension
Current Status
Recommended Action
Timeline
Key-man insurance
Likely absent
Implement for top 5 doctors within 90 days
Q3 FY26
Retention agreements
Assumed basic
Strengthen with long-term incentives & equity
Q3 FY26
Mentorship program
Ad-hoc
Formalize junior specialist development under senior leads
Q4 FY26
Case load diversification
High concentration
Develop co-leadership model; train junior docs in high-revenue cases
FY27
📊 Monthly Performance Highlights
Jan'26 peak revenue of ₹37.41 Cr reflects strong month-end collections and seasonal surge. YTD monthly average ₹35.86 Cr. IP discharges grew from 1,842 (Apr) to 1,963 (Jan) — +6.6% monthly trend. Occupancy recovered from Oct trough (58.9%) to Jan peak (63.8%). Seasonality pattern shows dips in Oct-Nov (post-monsoon utilization), recovery in Dec-Jan. OP footfall stable at 33K+/month average across year.
Monthly Revenue Trend (IP vs OP Stacked)
10-month period April 2025 - January 2026
IP Discharges & Occupancy Trend
Case volume and bed utilization monthly movement
Top 5 Departments - Monthly Revenue Trend
Tracking leading specialty performance across year
Month-by-Month KPI Summary
Detailed monthly performance metrics
Month
Revenue (Cr)
IP Rev (Cr)
OP Rev (Cr)
IP Disc
OP Footfall
ALOS
Occ %
Trend
Cash Payor Mix
68.2%
₹244.56 Cr
Insurance/TPA Mix
26.4%
₹94.67 Cr
Government Schemes
3.8%
₹13.63 Cr
Corporate Mix
1.6%
₹5.74 Cr
Insurance Growth
+4.2 ppt
vs FY24 (22.2%)
Diversification Score
Moderate
68% cash dependent
✓ Insurance Penetration Expansion
Insurance/TPA mix improved from FY24's 22.2% to FY26's 26.4% — a 4.2 ppt increase representing ₹94.67 Cr revenue. This diversification reduces cash collection risk and provides revenue stability. Government schemes (₹13.63 Cr, 3.8%) provide targeted social impact. Corporate mix remains underdeveloped (1.6%) — opportunity for B2B expansion. Still heavily cash-dependent (68.2%), requiring proactive collection management and credit quality monitoring.
Payor Mix Composition (YTD Jan'26)
Revenue distribution by payment source
FY24 vs FY26 YTD Payor Mix Comparison
Insurance penetration improvement
ARPP-IP by Department (Top 15)
Average revenue per inpatient across specialties
ARPOB by Department (Top 15)
Average revenue per occupied bed (annual basis)
Payor Mix Details by Department
Cash vs Insurance split across major specialties
Department
Total (Cr)
Cash %
Insurance %
Govt %
Avg Case Value (₹)
Nephrology
62.80
65
28
7
3,46,164
Medical Oncology
56.42
72
25
3
1,00,369
GI Surgery
28.14
68
28
4
1,88,906
Liver Transplant
18.92
78
18
4
5,07,018
Gastroenterology
22.18
70
25
5
1,42,788
Cardiology
21.54
66
30
4
1,56,747
Emergency Medicine
5.34
52
38
10
71,218
Gen Medicine
8.12
58
35
7
48,221
FY26 Revenue (Annualized)
₹430.32 Cr
Based on YTD avg
Revenue Growth
+8.4%
vs FY24 ₹397 Cr
IP Revenue Growth
+7.4%
vs FY24 ₹298 Cr
OP Revenue Growth
+11.4%
vs FY24 ₹99 Cr
Discharge Growth
+9.4%
vs FY24: 20,932
Occupancy Improvement
+7.6 ppt
vs FY24: 54.4%
✓ Solid Growth Trajectory Despite FY26 Budget Miss
FY26 annualized revenue of ₹430.32 Cr represents 8.4% YoY growth over FY24's ₹397 Cr, demonstrating LHRC's upward trajectory. OP revenue growth of 11.4% outpaces IP growth (7.4%), indicating successful outpatient expansion strategy. IP discharge volume up 9.4% (22,910 vs 20,932) showing increased case acquisition. Most impressive: bed occupancy improved 7.6 ppts to 62.0%, indicating better capacity utilization post-COVID normalization. Insurance mix shift (+4.2 ppt) reflects payer diversification. Growth deceleration vs budget (-3.1%) suggests market headwinds but underlying momentum remains strong.
FY24 vs FY26 Annualized Comparison
YTD comparison with annualized FY26 forecast
Metric
FY24
FY26 Annualized
Change
Growth %
Total Revenue (Cr)
397.00
430.32
+33.32
+8.4%
IP Revenue (Cr)
298.00
320.05
+22.05
+7.4%
OP Revenue (Cr)
99.00
110.27
+11.27
+11.4%
IP Discharges
20,932
22,910
+1,978
+9.4%
ARPP-IP (₹L)
1.42
1.40
-0.02
-1.4%
Bed Occupancy %
54.4
62.0
+7.6
+14.0%
Insurance Mix %
22.2
26.4
+4.2
+18.9%
Revenue Growth: FY24 to FY26
IP and OP revenue expansion comparison
Key Growth Drivers
Volume vs pricing contribution analysis
Top Departments: FY24 vs FY26 Growth
YoY growth rates across leading specialties
Department
FY24 (Cr)
FY26 Ann (Cr)
Growth %
Rank
Nephrology
66.18
75.36
+13.9%
1
Medical Oncology
54.91
67.70
+23.3%
2
GI Surgery
26.17
33.77
+29.0%
3
Neuro Surgery
20.88
29.83
+42.9%
4
Gastroenterology
19.75
26.62
+34.8%
5
Cardiology
18.24
25.85
+41.7%
6
FY26 Budget Target
₹370.00 Cr
Full year
FY28 Growth Target
₹530.00 Cr
+23% vs FY26 ann.
Required Growth Rate
11.0% CAGR
FY26-FY28
100-Day Priority
₹42.00 Cr
Revenue bridge
FY27 Target
₹462.00 Cr
7.5% growth
Occupancy Target
68.0%
vs current 62%
✓ Strategic Vision: Path to ₹530 Cr by FY28
Ambitious yet achievable growth trajectory from current ₹430.32 Cr (FY26 annualized) to ₹530 Cr by FY28 (+23% growth, 11.0% CAGR). Requires sustained focus on 5 pillars: (1) IP discharge volume recovery to 25,000+ annually, (2) ARPP optimization through case mix shift toward high-value procedures, (3) Occupancy improvement to 68%, (4) OP segment expansion to ₹140+ Cr, (5) Insurance/TPA growth to 35% mix. Strong Jan'26 performance (₹37.41 Cr) provides momentum for H2 FY26 bridge.
100-Day Execution Plan (Feb-Apr 2026)
Critical initiatives for gap closure and momentum
Priority
Initiative
Target
Owner
Exec Status
P0
IP discharge volume acceleration — target 2,100/month avg
+300 cases in Q4
COO
In Progress
P0
Case mix optimization — shift to high-ARPP cases (Nephro, Neuro, Liver)
+₹2.5 Cr revenue
CMO
Planning
P0
Occupancy recovery — deep-dive on underutilized departments
65%+ occupancy
Ops Head
Planning
P1
Insurance revenue growth — expand TPA partnerships +5 new partners
28% TPA mix
BD Head
In Progress
P1
OP expansion — scale clinic footprint to 5 additional centers
₹12 Cr OP revenue
Ops Head
Planning
P1
Doctor retention — finalize incentive redesign for top 5
100% retention
HR Head
Completed
P2
Emerging department support — nurture high-growth specialties
GI Surgery +15%, Neuro +12%
CMO
Planning
P2
Digital health integration — launch telemedicine platform
500 consultations/month
CIO
Planning
Revenue Bridge: FY26 Budget Target
Gap closure roadmap to ₹370 Cr (₹11.40 Cr shortfall)
FY28 Growth Bridge: ₹430 Cr → ₹530 Cr
2-year CAGR and annual milestone targets
Year
Target (Cr)
vs Prior YoY
Growth %
Key Driver
FY26 (Full Year, est)
430.32
+33.32
+8.4%
Volume + occupancy
FY27 Target
462.00
+31.68
+7.4%
Volume + case mix
FY28 Target
530.00
+68.00
+14.7%
Expansion + premium cases
Risk Register & Mitigation
Key execution risks and contingency plans
Risk
Impact
Mitigation
Owner
Top doctor departure (Nephro/Oncology)
High: -₹50+ Cr
Retention bonuses, key-man insurance, mentorship
CEO/HR
Competitive pressure on case mix
Medium: -₹5-10 Cr
Superior outcomes marketing, referral partnerships
LHRC ranks as #2 regional player in South India with ₹430.32 Cr annualized revenue (FY26), ~15% smaller than Apollo Health's ₹500+ Cr but stronger on occupancy metrics (62% vs Apollo's 59.2%). Superior ARPP-IP of ₹1.40L vs peers' ₹1.35L demonstrates premium positioning on case mix. Key gap: insurance penetration at 26.4% lags peer average (31.9%), representing 5.5 ppt opportunity. Neuro, GI Surgery, and Transplant programs competitive advantages vs IHH network. Strategic focus on insurance growth and occupancy optimization can close peer gap within 18 months.